<?xml version="1.0" encoding="UTF-8"?>
<p>HCMV is spread through various routes including sexual contact, organ and stem cell transplantation, breast milk and from mother to baby (transplacental) during pregnancy. Women can reduce HCMV transmission through practicing appropriate hygiene behaviors [
 <xref rid="B41-viruses-12-00110" ref-type="bibr">41</xref>,
 <xref rid="B42-viruses-12-00110" ref-type="bibr">42</xref>,
 <xref rid="B43-viruses-12-00110" ref-type="bibr">43</xref>,
 <xref rid="B44-viruses-12-00110" ref-type="bibr">44</xref>]. In seropositive pregnant women HCMV hyperimmunoglobulin is applied as passive immunization to improve the adaptive immune response and reduce the risk of congenital infection. However, the value of this treatment is controversial with limited data supporting improved clinical outcomes [
 <xref rid="B45-viruses-12-00110" ref-type="bibr">45</xref>,
 <xref rid="B46-viruses-12-00110" ref-type="bibr">46</xref>,
 <xref rid="B47-viruses-12-00110" ref-type="bibr">47</xref>,
 <xref rid="B48-viruses-12-00110" ref-type="bibr">48</xref>,
 <xref rid="B49-viruses-12-00110" ref-type="bibr">49</xref>]. The development of active immunization for HCMV is a major public health priority, and a number of candidate vaccines have been evaluated in clinical trials as well as preclinical models. However, no effective vaccine for HCMV is currently available [
 <xref rid="B50-viruses-12-00110" ref-type="bibr">50</xref>,
 <xref rid="B51-viruses-12-00110" ref-type="bibr">51</xref>,
 <xref rid="B52-viruses-12-00110" ref-type="bibr">52</xref>,
 <xref rid="B53-viruses-12-00110" ref-type="bibr">53</xref>,
 <xref rid="B54-viruses-12-00110" ref-type="bibr">54</xref>,
 <xref rid="B55-viruses-12-00110" ref-type="bibr">55</xref>,
 <xref rid="B56-viruses-12-00110" ref-type="bibr">56</xref>].
</p>
